论文部分内容阅读
目的:补肾化瘀豁痰法联合硝酸异山梨酯片对冠心病心绞痛痰浊阻痹证患者脂代谢及临床症状指标的影响。方法:选取2013年12月~2015年10月我院收治的82例冠心病心绞痛痰浊阻痹证患者为研究对象,随机数字表法均分为联合组及常规组各41例,常规组给予常规西药治疗,联合组另实施补肾化瘀豁痰法治疗,观察治疗后2组临床疗效、血脂指标[三酰甘油(TG)、血清总胆固醇(TC)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)]、临床症状指标[心绞痛发作次数、每次持续时间、每周硝酸甘油用量]及药物安全性。结果:治疗后联合组总有效率87.80%显著高于常规组63.41%(P<0.05);治疗前2组TG、TC、LDL、HDL、心绞痛发作次数、每次持续时间、每周硝酸甘油用量相较无明显差异(P>0.05);治疗后2组TG、TC、LDL较治疗前明显降低,HDL明显升高,心绞痛发作次数、每次持续时间、每周硝酸甘油用量显著减少,且联合组各项指标的变化程度较常规组明显,有统计学意义(P<0.05);治疗后联合组药物不良反应总发生率17.07%显著低于常规组36.59%,对比有统计学意义(P<0.05)。结论:补肾化瘀豁痰法联合硝酸异山梨酯片治疗冠心病心绞痛痰浊阻痹证患者的临床疗效显著,能有效调节患者血脂水平、改善临床症状。
Objective: To investigate the effects of tonifying kidney and removing phlegm method and isosorbide dinitrate tablets on lipid metabolism and clinical symptoms in patients with coronary heart disease and phlegm blocking stasis syndrome. Methods: From December 2013 to October 2015 in our hospital, 82 cases of patients with angina pectoris of phlegm blocking Bi Syndrome were selected as the research object, random number table method were divided into the combined group and the conventional group of 41 cases, the conventional group Conventional western medicine treatment, combined with another group of the implementation of the method of tonifying the kidney and removing phlegm, to observe the clinical efficacy of two groups after treatment, blood lipid indicators [triglyceride (TG), serum total cholesterol (TC), low density lipoprotein (LDL) (HDL), clinical symptoms (number of angina attacks, duration, weekly nitroglycerin use) and drug safety. Results: The total effective rate in the combined group after treatment was 87.80%, significantly higher than that in the conventional group (63.41%, P <0.05). The TG, TC, LDL, HDL, the number of angina pectoris, the duration of each treatment, the amount of nitroglycerin (P> 0.05). The TG, TC and LDL of two groups were significantly lower than those before treatment, HDL was significantly increased, the number of angina pectoris episodes, the duration of each episode, the weekly dosage of nitroglycerin significantly decreased, and the combined (P <0.05). The total incidence of adverse drug reactions in the combined group was 17.07%, which was significantly lower than that in the conventional group (36.59%, P <0.05), and the difference was statistically significant 0.05). Conclusion: Bushenhuayuhuatan combined with isosorbide mononitrate tablets in patients with coronary heart disease phlegm blocking Bi Syndrome significant clinical efficacy, can effectively regulate the patient’s blood lipid levels and improve clinical symptoms.